Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol 1990;83(3):149-51

Date

01/01/1990

Pubmed ID

2109455

DOI

10.1159/000205193

Scopus ID

2-s2.0-0025270769 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

A patient whose chronic myelogenous leukemia (CML) was treated with interferon alpha (IFN-alpha) is described. The disease showed karyotypic evolution during the chronic phase and the later myeloid acceleration. Both of these secondary clonal phenomena responded to IFN-alpha dose escalation. The case illustrates the dose dependence of CML responses to IFN-alpha. The phenomenon of clonal evolution is discussed in the context of this patient's disease.

Author List

Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Clone Cells
Humans
Interferon Type I
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged